174 - How GLP-1s Like Ozempic & Wegovy Are Changing Pharma with Ben Locwin
Ben Locwin, a healthcare executive and quality/regulatory subject matter expert, discusses the science, manufacturing, and regulatory landscape of GLP-1 receptor agonists like Ozempic and Wegovy. He explains that while these drugs have a long development history dating back to the 1970s, their recent commercial success has created massive capacity constraints for CDMOs and significant sustainability issues regarding the disposal of billions of auto-injector pens. Locwin highlights the regulatory arbitrage in the compounding space, where 503B facilities face fewer advertising restrictions than branded manufacturers, and notes the industry's shift toward longer-acting synthetic molecules like semaglutide to improve patient compliance.